Evaluation of the impact of ugt polymorphism on the pharmacokinetics and pharmacodynamics of the novel ppar agonist sipoglitazar

Journal of Clinical Pharmacology

Volumn 53, Issue 3, 2013, Pages 256-263

  Stringer, Frances ^a   Ploeger, Bart A ^b   De Jongh, Joost ^b,c   Scott, Graham ^d   Urquhart, Richard ^a   Karim, Aziz ^e   Danhof, Meindert ^b,c  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b LEIDEN UNIVERSITY   (Netherlands)

^c LAP and P Consultants BV   (Netherlands)

^d Takeda Global Research and Development   (United Kingdom)

^e Takeda Global Research and Development   (United States)

Author keywords

Genetics; Glucuronosyltransferase; Metabolism; Pharmacokinetics

Indexed keywords

GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 2B15; HEMOGLOBIN A1C; PLACEBO; SIPOGLITAZAR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POPULATION MODEL; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; POLYMORPHISM, GENETIC; PROPIONATES; THIAZOLES; YOUNG ADULT;

EID: 84877138025     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270012447121     Document Type: Article

References (28)

1. Frueh FW, Salerno RA, Lesko LJ, et al. 4th US FDA-Drug Information Association pharmacogenomics workshop, held 10-12 December, 2007. Pharmacogenomics. 2009;10(1):111-115.
2. Peters J. Eyes on the prize: bringing individualized therapy from the bedside to clinical practice. Pharmacogenomics. 2007;8(10): 1295-1298.
3. Aleil B, Leon C, Cazenave JP, et al. CYP2C19*2polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring. J Thromb Haemost. 2009;7(10): 1747-1749.
4. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev. 2006;58(3):521-590.
5. Guillemette C. Pharmacogenomics of human UDP-glucurono syltransferase enzymes. Pharmacogenomics J . 2003;3(3):136-158.
6. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood. 2000;96(5):1816-1819.
7. Lennard MS, Silas JH, Freestone S, et al. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. Br J Clin Pharmacol. 1982;14(2):301-303.
8. Chung JY, Cho JY, Yu KS, et al. Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther. 2005;77(6):486-494.
9. He X, Hesse LM, Hazarika S, et al. Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. Br J Clin Pharmacol . 2009;68(5):721-730.
10. Levesque E, Beaulieu M, Green MD, et al. Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics. 1997;7(4):317-325.
11. Lampe JW, Bigler J, Bush AC, et al. Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y). Cancer Epidemiol Biomarkers Prev. 2000;9(3):329-333.
12. Nishihara M, Sudo M, Kawaguchi N, et al. An unusual metabolic pathway of sipoglitazar, a novel anti-diabetic agent: cytochrome P450-Catalyzed oxidation of sipoglitazar acyl glucuronide. Drug Metab Dispos. 2011;34:1220-1128.
13. Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA: the amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989;17(7):2503-2516.
14. Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J . 2009;11(3):558-569.
15. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303-332.
16. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001;28(3):231-252.
17. Post TM, Freijer JI, Ploeger BA, et al. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn. 2008;35(2):185-202.
18. Levesque E, Delage R, Benoit-Biancamano MO, et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther. 2007;81(3): 392-400.
19. Yukawa E, Mamiya K. Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using non-linear mixed effects model approach. J Clin Pharm Ther. 2006;31(3):275-282.
20. Tanigawa T, Heinig R, Kuroki Y, et al. Evaluation of interethnic differences in repinotan pharmacokinetics by using population approach. Drug Metab Pharmacokinet. 2006;21(1):61-69.
21. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360(4):354-362.
22. Brynne N, Dalen P, Alvan G, et al. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther . 1998;63(5):529-539.
23. Food and Drug Administration. Briefing document for voriconazole (oral and intravenous formulations). http://www.fda.gov/ohrms/dockets/ac/01/briefing/ 3792b2-01-Pfizer.pdf. Accessed November 15, 2010.
24. Food and Drug Administration. Table of valid genomic biomarkers in the context of approved drug labels. http://www.fda.gov/Drugs/ScienceResearch/ ResearchAreas/Pharmacogenetics/ucm083378 .htm. Updated August 18, 2009. Accessed November 15, 2010
25. Suzuki K, Yanagawa T, Shibasaki T, et al. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract . 2006;72(2):148-154.
26. Sakurai Y, Hirayama M, Hashimoto M, et al. Population pharmacokinetics and proton pump inhibitory effects of intravenous lansoprazole in healthy Japanese males. Biol Pharm Bull. 2007;30(12):2238-2243.
27. Chahal H, Chowdhury TA. Gliptins: a new class of oral hyperglycaemic agent. Q J Med. 2007;100:671-677.
28. Bailey CJ, Day C. Thiazolidinediones today. Br J Diabetes Vasc Dis. 2001;1:7-13.